To compare if the motility marker CCR5 was associated with higher tumor-associated cell prevalence in the circulation, we compared patients with high average CCR5 pools against the prevalence of TACs (CTCs or CAMLs) in the blood. This evidence concerns the gene CCR5 and neoplasm.